Skip to main content

Advertisement

Table 4 Summary of positive rates of CTL responses to each peptide antigen

From: Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients

Positive rates of CTL responses to each antigen in all patients (n = 11)
Number of vaccination URLC10 (%) TTK (%) KOC1 (%) VEGFR1 (%) VEGFR2 (%) CMV (%)
Pre-vac. 27.3 (3/11) 36.4 (4/11) 40.0 (4/10) 20.0 (2/10) 40.0 (4/10) 100.0 (10/10)
4 70.0 (7/10) 27.3 (3/11) 45.5 (5/11) 33.3 (3/9) 45.5 (5/11) 100.0 (11/11)
8 54.5 (6/11) 36.4 (4/11) 45.5 (5/11) 45.5 (5/11) 36.4 (4/11) 100.0 (11/11)
12 100.0 (5/5) 40.0 (2/5) 60.0 (3/5) 40.0 (2/5) 80.0 (4/5) 100.0 ( 5/ 5)
16 100.0 (5/5) 40.0 (2/5) 60.0 (3/5) 60.0 (3/5) 80.0 (4/5) 100.0 ( 5/ 5)
  1. CTL positive rates on the pre-vaccination, 4th, 8th, 12th or 16th vaccination were examined in all patients (n = 11), CR patients (n = 6) and PD patients (n = 5). When the ELISPOT Assay indicated +, ++ or +++, we judged it to be positive case. *p values.